Almirall/Forest delay filing of Eklira until 2011
This article was originally published in Scrip
Executive Summary
In light of data showing that Almirall/Forest Laboratories' long-acting muscarinic antagonist (LAMA) Eklira (aclidinium bromide) for chronic obstructive pulmonary disease (COPD) is more effective as a twice-daily than as a once-daily formulation, the companies are delaying filing of the drug by over a year. They had previously said they would file a once-daily formulation of the drug early this year, but now say that they will only file a twice-daily formulation in 2011.